Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human visugromab alone and with anti-PD-1 in advanced relapsed/refractory solid tumors
2024-512575-12-00Phase 2Authorised
- Sponsor
- CatalYm
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of visugromab in Nonhematologic neoplasms, bladder cancer, hepatocellular carcinoma (HCC) and 3 more (3 arms), sponsored by CatalYm. Primary endpoints: Clinical efficacy by RECIST v1.1 and Safety and tolerability. Planned start Jul 2024; status: authorised.
02
Drugs
visugromab
03
Conditions
Nonhematologic neoplasmsbladder cancerhepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on 2024-512575-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512575-12-00.